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Abstract
Background—Aggressive diagnosis and treatment of patients presenting to the emergency 
department (ED) with septic shock has been shown to reduce mortality. To enhance the ability to 
intervene in patients with lesser illness severity, a better understanding of the natural history of the 
early progression from simple infection to more severe illness is needed.
Objectives—The objectives were to 1) describe the clinical presentation of ED sepsis, including 
types of infection and causative microorganisms, and 2) determine the incidence, patient 
characteristics, and mortality associated with early progression to septic shock among ED patients 
with infection.
Methods—This was a multicenter study of adult ED patients with sepsis but no evidence of 
shock. Multivariable logistic regression was used to identify patient factors for early progression 
to shock and its association with 30-day mortality.
Results—Of 472 patients not in shock at ED presentation (systolic blood pressure > 90 mm Hg 
and lactate < 4 mmol / L), 84 (17.8%) progressed to shock within 72 hours. Independent factors 
associated with early progression to shock included older age, female sex, hyperthermia, anemia, 
comorbid lung disease, and vascular access device infection. Early progression to shock (vs. no 
progression) was associated with higher 30-day mortality (13.1% vs. 3.1%, odds ratio [OR] = 
4.72, 95% confidence interval [CI] = 2.01 to 11.1; p ≤ 0.001). Among 379 patients with 
uncomplicated sepsis (i.e., no evidence of shock or any end-organ dysfunction), 86 (22.7%) 
progressed to severe sepsis or shock within 72 hours of hospital admission.
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Conclusions—A significant portion of ED patients with less severe sepsis progress to severe 
sepsis or shock within 72 hours. Additional diagnostic approaches are needed to risk stratify and 
more effectively treat ED patients with sepsis.
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The emergency department (ED) is a common location for the initial evaluation and 
management of patients with sepsis. Infection-related conditions account for over 10 million 
ED visits in the United States annually, sepsis causes an estimated 750,000 deaths per year; 
and it is the 10th leading cause of death overall.1–3 However, the initial evaluation of 
patients with suspected infection in the ED is complicated by 1) the lack of specificity of 
systemic inflammatory response syndrome (SIRS) criteria for infection;4,5 2) the 
heterogeneity of clinical manifestations, including clinical signs and symptoms, site of 
infection, comorbid conditions, and etiologic microorganisms;6,7 and 3) the challenge in 
rapidly identifying patients most likely to progress to severe illness or death, especially 
among patients who are not severely ill at initial evaluation.
Patients who are identified as high risk (persistent hypotension and / or lactate levels greater 
than 4 mmol /L) who present to the ED are candidates for early protocolized intervention, 
which includes addressing the infectious source and aggressive resuscitation. Early goal-
directed therapy (EGDT) initiated in the ED has been shown to reduce mortality, especially 
in patients with hemodynamic compromise.8,9 However, risk assessment and optimal 
management for patients with suspected infection without shock at initial presentation to the 
ED are less clear. There is a critical need for rapid, accurate, and early identification of 
patients at risk for disease progression and hemodynamic compromise given the availability 
of time-sensitive treatment regimens such as EGDT and recombinant activated protein C.8,10 
Yet, the overall incidence and adverse outcomes of early clinical progression in patients 
with sepsis in the ED have not been well studied.
The objective of this prospective, multicenter cohort study of patients presenting to the ED 
with sepsis was to 1) describe the clinical presentation of sepsis, including types of infection 
and causative microorganisms; 2) to determine the incidence and mortality associated with 
early progression to septic shock among ED patients with infection; and 3) to evaluate 
patient characteristics associated with early progression to septic shock.
METHODS
Study Design
This was a secondary analysis of data collected for a larger study: the Community Acquired 
Pneumonia & Sepsis Outcome Diagnostics (CAPSOD) study, which was a prospective, 
multicenter National Institutes of Health–sponsored study to develop novel diagnostic and 
prognostic tests for severe sepsis and community-acquired pneumonia in the ED 
(ClinicalTrials.gov identifier NCT00258869). This study was approved by the institutional 
Glickman et al. Page 2






















review board at each institution, and written, informed consent was obtained from all study 
participants or their legal designates.
Study Setting and Population
Patient enrollment was conducted at three EDs: Duke University Medical Center in Durham, 
North Carolina (annual census 65,000 patients); the Veterans Affairs Medical Center in 
Durham, North Carolina (annual census 40,000 patients); and the Henry Ford Hospital in 
Detroit, Michigan (annual census 95,000 patients). Subjects were screened primarily during 
daytime weekday hours in the ED between 2005 and 2007. Patients were eligible if they had 
a known or suspected infection and if they exhibited two or more SIRS criteria.5 Patients 
were excluded if they had an imminently terminal comorbid condition or advanced AIDS 
(CD4 count < 50 / μL), were being treated with an antibiotic, or were participating in an 
ongoing clinical trial.
A total of 730 patients over 18 years of age were enrolled. Because the primary objective of 
this analysis was to determine the incidence of progression to shock among patients not 
initially in shock at the time of evaluation in the ED (i.e., patients not generally considered 
candidates for protocolized resuscitation), patients who were hypotensive despite fluid 
resuscitation or who had a lactate level of >4 mmol /L were not included in the analysis (n = 
152). An additional 106 patients were later determined not to have an infection and were 
also excluded from the analysis. The final data set used for analysis contained 472 patients 
with confirmed infection who were not in shock at the time of enrollment in the ED (Figure 
1).
Study Protocol
After informed consent was obtained, patients or their representative were asked by trained 
research assistants to complete a standardized questionnaire including demographics and 
symptoms. A microbiologic evaluation included two sets of blood cultures, urine culture, 
pneumococcal urinary antigen test, and cultures of other sites as clinically indicated. Other 
baseline measurements included a complete blood count, blood chemistries, urinalysis, and 
chest radiographs. Trained study coordinators at each site recorded vital signs and laboratory 
and imaging results from the initial ED encounter and at 24-hour intervals for up to 72 hours 
or until death. After 30 days, in-hospital mortality and microbiologic culture results were 
determined from the patients’ medical records. All data were collected in electronic case 
report forms with decision support logic and stored in a HIPAA-compliant database 
(Prosanos Inc., Harrisburg PA).
Adjudication of Infections and Patient Outcomes—Adjudication of all patient 
records with respect to infection status was conducted at least 30 days after hospital 
discharge. Determination of infection status and patient outcome was made by a study 
physician, board certified in emergency medicine (SWG), after review of all study data and 
patient medical records. Infection status was categorized as follows: 1) infection and 
causative organism identified; 2) infection, but causative organism not identified; or 3) 
infection unlikely. Causative organisms were classified as 1) at least one positive blood 
culture for Staphylococcus aureus, Gram-negative bacteria, Candida albicans, or 
Glickman et al. Page 3






















Streptococcus pneumoniae; 2) two or more positive blood cultures for another single 
organism; 3) a positive culture from another sterile source (e.g., cerebrospinal, joint); or 4) a 
positive urinary pneumococcal antigen with a clinical picture compatible with pneumonia.
For patients not clearly meeting the above criteria for infection by the primary adjudicator, 
the medical records were reviewed by a second investigator who was board certified in 
internal medicine and infectious diseases (CWW). A third individual with specialty training 
in internal medicine and infectious diseases (ELT) performed an independent adjudication of 
a sample of 10% of the patient records. Agreement on the infection classification between 
this individual and the primary adjudicator was high (κ = 0.82), exceeding the 0.80 threshold 
considered “almost perfect agreement.”11
Study Definitions—Patients were categorized as having uncomplicated sepsis, severe 
sepsis, or septic shock at the time of study enrollment and at each subsequent 24-hour 
interval during their hospitalizations. Uncomplicated sepsis was defined as sepsis without 
evidence of shock or end-organ dysfunction. Severe sepsis was defined as two or more SIRS 
criteria with evidence of end-organ dysfunction (including metabolic [lactate > 1.5 times 
upper limit of normal or arterial pH < 7.30], hematologic [platelet count < 80 × 103], 
pulmonary [intubation or PaO2 / FiO2 < 250], renal [urine output < 0.5 mL / kg / hr despite 
adequate fluid resuscitation], or cardiac [mean arterial pressure (MAP) < 65 mm Hg or 
systolic blood pressure (sBP) < 90 mm Hg despite adequate fluid resuscitation]).12,13 Septic 
shock was defined as tissue hypoperfusion, including hypotension (sBP < 90 mm Hg or 
MAP < 65 mm Hg) persisting despite initial fluid challenge or a blood lactate concentration 
equal to or greater than 4 mmol / L.12,13 Early progression to septic shock was defined as 
development of shock within the first 72 hours after enrollment among patients who had no 
evidence of shock upon initial evaluation in the ED.
Data Analysis
Baseline patient demographics, clinical signs and symptoms, infection classification, and 
outcomes were compiled. Median values with interquartile ranges (IQRs) were used to 
describe continuous variables, and numbers with percentages were reported for categorical 
variables.
A multiple variable logistic regression model was performed to identify patient 
characteristics associated with progression to septic shock within 72 hours of ED 
presentation. The dependent variable was defined as the presence of shock (yes / no) within 
72 hours of initial evaluation in the ED. Predictor variables included information available 
to the treating emergency physician, including demographics, vital signs, and laboratory 
values. The adjudicated infection site and causative microorganism were also included as 
predictor variables. Candidate variables were screened using univariate analysis. Variables 
significant at p < 0.20 were selected and included in a final multivariable logistic regression 
model using backward selection. Additional models using forward selection and stepwise 
techniques were performed and yielded nearly identical results. Continuous predictor 
variables were explored for nonlinearity in the models after categorizing them into quartiles. 
There were no significant nonlinearities, so they were modeled as continuous variables. 
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Variables significant at p < 0.05 were retained in the final multivariable models. A Kaplan-
Meier survival analysis was performed to evaluate the temporal association of early 
progression to septic shock with 30-day mortality.
Additional analyses were performed to determine the incidence of disease progression to 
severe sepsis or shock within the first 72 hours among a subgroup of patients with 
uncomplicated sepsis (i.e., no evidence of shock or any end-organ dysfunction) at the time 
of enrollment. The numbers and percentages of patients with uncomplicated sepsis who 
progressed to severe sepsis or shock were determined. The time to occurrence of severe 
sepsis or shock stage among patients with uncomplicated sepsis was estimated using 
cumulative incidence up to 72 hours.
The association between sepsis treatment and progression to shock was evaluated based on 
whether a patient received appropriate antibiotic therapy within the first 24 hours of 
evaluation in the ED. Antimicrobial susceptibility of causative agents was used as the basis 
for determining appropriateness of antibiotic therapy.14,15 Therapy was considered 
appropriate when at least one effective drug was administered within 24 hours.16 All 
analyses were performed using SAS, Version 9.1.2 (SAS Institute, Cary, NC). A p value of 
<0.05 was considered statistically significant.
RESULTS
A total of 472 patients over 18 years of age with confirmed infection who were not in shock 
at the time of initial ED evaluation were enrolled (Table 1). Lung, urine, and skin were the 
most common adjudicated infection sites (34.3, 14.0, and 13.8%, respectively; Table 2). The 
most common causative microorganisms were S. aureus (26.0%), Escherichia coli (16.9%), 
other aerobic Gram-negative bacilli (e.g., Klebsiella spp. or Enterobacter spp.; 20.3%), and 
S. pneumoniae (16.9%).
Of the 472 patients with infection who were not in shock at the time of enrollment, 84 
(17.8%) progressed to septic shock within 72 hours. Factors associated with early 
progression to septic shock included older age, female sex, higher body temperature, 
anemia, comorbid lung disease, and infection associated with an indwelling vascular 
catheter (Table 3). Early progression to septic shock was associated with time to death 
(Kaplan-Meier log-rank χ2 = 14.4, p = 0.001; Figure 2). Early progression to shock (vs. no 
progression) was associated with higher 30-day mortality (13.1% vs. 3.1%, odds ratio [OR] 
= 4.72, 95% CI = 2.01 to 11.1; p ≤ 0.001).
Of the 472 patients with confirmed infection not in shock at the time of enrollment, 93 had 
severe sepsis (Figure 3). The remaining 379 patients had no evidence of end-organ 
dysfunction and were categorized as having uncomplicated sepsis. Of the 379 patients with 
uncomplicated sepsis, 86 (22.7%) developed severe sepsis or septic shock within 72 hours 
(Figure 4). Progression occurred early during the hospital stay; the cumulative incidences of 
severe sepsis or shock at 24 and 48 hours were 13.5 and 21.4%, respectively. Among 
patients with uncomplicated sepsis, the cumulative incidence of death by Day 30 was 3.4%. 
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The 30-day mortality rate in patients with early progression was 8.0% versus 2.0% in 
patients without early progression (χ2 = 5.72, p = 0.02).
Of the 177 patients with definite infection and a confirmed causative microorganism, 174 
had a bacterial or fungal etiology. Among these patients, 167 of 174 (96.0%) patients 
received appropriate antibiotics within the first 24 hours of ED presentation. The use of 
appropriate antibiotics was similar in patients who progressed to shock within 72 hours (37 
of 38, 97.4%) and those who did not progress to shock (130 of 136, 95.8%).
DISCUSSION
Patients who are identified as high risk of sepsis (persistent hypotension and / or lactate 
levels of ≥4 mmol / L) who present to the ED are candidates for early protocolized 
intervention, which includes early antibiotic therapy, source identification and control, and 
aggressive resuscitation.6 The optimal diagnostic and management strategies for ED patients 
with less severe sepsis have not been determined, nor has its early natural history been well 
described. This study found that nearly one in five patients with sepsis who were not in 
shock upon presentation to the ED developed septic shock within 72 hours. Patient factors 
associated with sepsis progression included older age, female sex, anemia, comorbid lung 
disease, hyperthermia, and vascular access infection. Early progression to septic shock was 
associated with higher 30-day mortality. Among a subgroup of 379 patients with 
uncomplicated sepsis, 86 (22.7%) progressed to severe sepsis or septic shock by 72 hours. 
This progression was observed despite appropriate antibiotic therapy.
To our knowledge, this is the first study that has examined the progression to severe sepsis 
or shock in a multicenter cohort of patients in the ED setting. Alberti et al.17 reported that 
among 1,531 patients in 28 intensive care units (ICUs) with a first episode of infection on 
admission or during the stay, the cumulative incidences of progression to severe sepsis or 
shock were 20 and 24%, on Days 10 and 30, respectively. While our 30-day cumulative 
incidence of severe sepsis and shock (24.8%) was similar to that reported by Alberti et al. 
(24.0%), disease progression occurred much earlier in our ED cohort (21.4% at 48 hours) 
than in the cohort of Alberti et al. (<5% at 48 hours). This may reflect underlying 
differences in the natural history of disease progression in patients with community-acquired 
sepsis seen in the ED versus nosocomial sepsis seen in the ICU. Alternatively, the difference 
in progression rates could reflect earlier diagnosis, earlier sepsis stage, or intensity of 
treatment in patients already hospitalized. The high incidence of early progression to severe 
sepsis and shock among patients presenting to the ED highlights its time-sensitive nature, 
even in patients who initially do not appear critically ill.
Hyperthermia at time of presentation was strongly associated with progression to septic 
shock within 72 hours. Perturbations of core temperature is a common finding in sepsis, and 
hyperthermia is one of the SIRS criteria that define sepsis.5 Early pyrexia in sepsis is 
believed to reflect elevated levels of endogenous, pyrogenic mediators (acute phase 
reactants), together with increased metabolic rate.18,19 Temperatures higher than 38.2°C in 
ICU patients with sepsis has been associated with progression to severe sepsis and shock on 
Days 10 and 30, respectively.17 The increase in systemic oxygen demands associated with 
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elevated temperatures exacerbate the imbalance between systemic oxygen supply and 
demands. This study extends the observation that pyrexia in patients without shock who 
present to the ED is similarly associated with an increased risk of early progression to septic 
shock.
Previous studies have examined the influence of race and sex on sepsis incidence and 
outcomes.20,21 The incidence of sepsis and sepsis-related mortality is reportedly lower in 
women, and several hypotheses have been proposed to explain this finding, including the 
role of sex hormones and sex-related gene polymorphisms associated with immune 
function.22 However, in our study conducted in an ED setting, women were twice as likely 
as men to progress to septic shock within 72 hours of presentation. Previous studies have 
reported sex disparities in treatment administered to patients with a variety of acute 
conditions, including acute myocardial infarction and patients hospitalized in ICU 
settings.23,24 We did not observe differences in the delivery of protocolized sepsis care or 
appropriate antibiotic utilization between women and men. Additional research is needed to 
confirm and explain sex differences in early sepsis progression.
Patients with vascular access device infections had the highest rate of progression to septic 
shock within 72 hours of admission (11 of 20, 55%). Catheter-related septicemia has been 
associated with poor outcomes and a nearly 30% attributable risk of mortality.25 Increased 
use of intravenous catheters for such things as maintenance dialysis or home drug delivery 
has resulted in significant ED utilization and costs.26 In a multicenter prospective study of 
1,846 hemodialysis patients, 23% of all infection-related hospitalizations were vascular 
access related, accounting for one-quarter of the 871 patient study deaths.27 In light of these 
findings, and the significance of vascular access–related infections as a risk factor for sepsis 
progression in our study, more aggressive management of uncomplicated sepsis may be 
indicated.
Previous studies have shown that elevated serum lactate levels are associated with higher 
mortality in ED patients with severe sepsis and shock.28–31 In our cohort of 730 patients, 
elevated lactate was an independent predictor of death. The 30-day mortality rate among 
patients with lactate levels of >4 mmol /L was 28.6%, similar to previous reports.30,31 Yet 
among patients in our study who were not hypotensive and had a serum lactate 
concentration of <4 mmol / L, higher lactate levels did not appear to predict early 
progression to septic shock. Elevated serum lactate may occur in later progression from 
sepsis to septic shock. In addition, lactate may be elevated for a variety of reasons, including 
impaired clearance, depressed cellular respiration secondary to insufficient oxygen tissue 
delivery, impaired microcirculation, and mitochondrial dysfunction.32–36 Thus, additional 
metabolic biomarkers may be needed to identify high-risk sepsis patients earlier while they 
are in the ED.
This study has several strengths in comparison to some previous sepsis studies. First, final 
determination of infection status was determined by blinded study physicians based on 
results of systematic blood cultures and other objective diagnostic tests. As a result, 15% of 
SIRS patients with suspected infection initially were later determined to have a 
noninfectious etiology. In contrast, previous studies of sepsis progression included SIRS 
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patients without evidence of confirmed infection. Second, this study focused on patients 
who were hemodynamically stable at the time of ED presentation, a subgroup that has been 
understudied in comparison with studies of patients with septic shock. In contrast, most 
previous studies of sepsis progression were conducted in hospitalized patients in the ICU 
and therefore involved sepsis of nosocomial origin. Finally, the present multicenter study 
included a diverse demographic group of patients, including African Americans, whereas 
previous studies of sepsis progression predominantly enrolled whites.
LIMITATIONS
This study involved three EDs and thus may not be generalizable to other ED settings with 
different patient characteristics, treatment patterns, and research personnel. Sepsis 
progression and patient outcomes are probably influenced by treatment. Thus, differences 
among providers and between institutions with respect to treatment may have influenced 
patient outcomes. Our findings, however, were consistent across the three study sites, and 
the low overall mortality rates may reflect systematic early detection and aggressive care for 
patients with severe sepsis. We did not observe any systematic differences in the use, timing, 
or appropriateness of antibiotic therapy or initial resuscitation.
Classification of septic shock is imperfect and complicated by the dynamic nature of the 
condition and challenges in obtaining precise clinical measurements. To address this issue, 
published definitions for septic shock were used at predetermined time points for all 
patients.
While screening and enrollment were available throughout all days of the week and all hours 
of the day at each site, most patients were enrolled during the daytime hours, given the need 
for prompt study specimen handling for metabolic studies. Thus, our study data may not be 
fully reflective of patient characteristics and ED treatment during nighttime and weekend 
hours.
Finally, while the overall mortality rate in our analysis cohort was only 4.9%, this is largely 
explained by the fact that we included a significant number of patients with uncomplicated 
sepsis in our analysis. The overall 30-day mortality rates in our larger patient cohort were 
28.6% for patients with lactate levels of ≥4 mmol /L and 35.2% for patients with 
concomitant hypotension, similar to rates reported in previous ED studies.30,31
CONCLUSIONS
Approximately one of every four patients with confirmed infection who presents to the ED 
with uncomplicated sepsis progresses to severe sepsis or septic shock within 72 hours. Early 
progression to septic shock (vs. no progression) is associated with higher 30-day mortality. 
Better diagnostic tools are needed to identify ED patients with sepsis who are at high risk for 
disease progression to organ dysfunction or shock, with the hope that early intervention in 
this group would improve patient outcomes.
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Study cohort. The study cohort at enrollment and subsequent patient outcomes at 72 hours 
and 30 days.
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Kaplan-Meier survival analysis: 30-day survival stratified by early progression (72 hours) to 
septic shock. The figure plots 30-day survival for patients with confirmed infection who 
were not in shock at the time of initial ED evaluation stratified by whether they developed 
septic shock within 72 hours of initial ED evaluation.
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Disease progression among patients with uncomplicated sepsis. Of the 472 patients who 
were not in shock at the time of enrollment, 93 had evidence of end-organ dysfunction. The 
remaining 379 patients had no evidence of end organ dysfunction and were categorized as 
having uncomplicated sepsis. Of these 379 patients with uncomplicated sepsis, 86 (22.7%) 
developed severe sepsis or septic shock within 72 hours.
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Cumulative incidence of severe sepsis or septic shock among ED patients with 
uncomplicated sepsis (i.e., no evidence of shock or end-organ dysfunction). The figure plots 
72-hour cumulative incidence of severe sepsis or septic shock among patients who had 
uncomplicated sepsis (i.e., no evidence of shock or end-organ dysfunction) at the time of 
initial ED evaluation. The cumulative incidences of severe sepsis or septic shock at 24, 28, 
and 72 hours were 13.5, 21.4, and 22.7%, respectively.
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Table 1
Characteristics of 472 Patients With Sepsis but No Evidence of Shock at the Time of ED Presentation
Variable
Age (yr), median (IQR) 52 (44–66)
Sex, n (%)
 Male 248 (52.5)
 Female 224 (47.5)
Race, n (%)
 African American 264 (55.9)
 White 186 (39.4)
 Other 22 (4.7)
Site, n (%)
 Duke, NC 246 (52.1)
 Henry Ford, MI 195 (41.3)
 Durham, NC 31 (6.6)
Apache II score, median (IQR) 9.0 (5.0–13.5)
Comorbidities, n (%)
 Alcohol abuse 41 (8.7)
 Cancer 37 (7.8)
 Chronic renal failure 60 (12.7)
 Chronic lung disease 108 (22.9)
 Cirrhotic liver disease 7 (1.5)
 Diabetes mellitus 132 (28.0)
 Drug use 55 (11.7)
 Heart failure 41 (8.7)
 Hemodialysis 47 (10.0)
 Human immunodeficiency virus 7 (1.5)
 Smoker 85 (18.0)
Clinical variables, median (IQR)
 Heart rate (beats / min) 109 (96–122)
 Respiratory rate (breaths / min) 20 (20–25)
 Temperature (°C) 38.3 (37.4–39.0)
 Blood pressure, mean arterial, mm Hg (IQR) 87 (78–98)
Laboratory values, median (IQR)
 Creatinine (mg / dL) 1.1 (0.9–1.6)
 Hematocrit (%) 37 (33–41)
 Platelet count (×103/μL) 246 (179–318)
 White blood cell count (×103/μL) 13.2 (9.1–16.7)
IQR = interquartile range.
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Table 2
Infection Sites, Causative Microorganisms, and Outcomes for 472 Patients With Sepsis but No Shock at the 
Time of ED Presentation
Total Shock Progression (Within First 72 Hours) Death (Within 30 Days)
Infection category
 Infection, organism identified 177 (37.5) 38 (21.5) 8 (4.5)
 Infection, organism not identified 295 (62.5) 46 (15.6) 15 (5.1)
 Total 472 (100) 84 (17.8) 23 (4.9)
Infection source
 Bone 13 (2.8) 4 (30.8) 1 (7.7)
 Cardiac 1 (0.2) 0 (0) 0 (0)
 Catheter 20 (4.2) 11 (55) 0 (0)
 Central nervous system 3 (0.6) 0 (0) 0 (0)
 Ear, nose, and throat 16 (3.4) 1 (6.3) 0 (0)
 Gynecologic 4 (0.8) 0 (0) 1 (25)
 Intraabdominal 47 (10) 5 (10.6) 1 (2.1)
 Pulmonary 162 (34.3) 23 (14.2) 13 (8.0) (11.1)
 Skin 65 (13.8) 8 (12.3) 1 (1.5)
 Urinary tract 66 (14) 11 (16.7) 1 (1.5)
 Unknown 75 (15.9) 21 (28) 5 (6.7)
 Total 472 (100) 84 (17.8) 23 (4.9) (15.5)
Infection causative organism*
 S. auereus 46 (26) 8 (17.4) 0 (0)
 S. pneumoniae 30 (16.9) 4 (13.3) 3 (10)
 Other Gram-positive cocci 12 (6.8) 4 (33.3) 2 (16.7)
 E. coli 30 (16.9) 3 (10) 0 (0)
 Aerobic Gram-negative bacilli 36 (20.3) 11 (30.6) 1 (2.8)
 Polymicrobial 4 (2.3) 3 (75) 0 (0)
 Fungi and Candida 3 (1.7) 1 (33.3) 0 (0)
 Anaerobes 9 (5.1) 1 (11.1) 0 (0)
 Viral 4 (2.3) 1 (25) 0 (0)
 Other 3 (1.7) 2 (66.7) 1 (33.3)
 Total 177 (100) 38 (21.5) 7 (4.0)
Values are n (%).
*
Includes only patients with infection where a causative organism was definitely identified (N = 177).
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